openPR Logo
Press release

Venous Thromboembolism Market Anticipated To Witness Robust Growth, Surpassing $3.02 Billion By 2029

05-23-2025 01:55 PM CET | Health & Medicine

Press release from: The Business Research Company

Venous Thromboembolism

Venous Thromboembolism

The Venous Thromboembolism Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Venous Thromboembolism Market Size and Its Estimated Growth Rate?
The market for venous thromboembolism has seen continuous expansion in the past years. It is projected to increase from $2.44 billion in 2024 to $2.55 billion in 2025, indicating a compound annual growth rate (CAGR) of 4.4%. This past growth is primarily due to factors such as growing elderly population, development in anticoagulants, reimbursement tactics, and heightened investments.

In the coming years, the market size for venous thromboembolism is projected to grow steadily. By 2029, it is anticipated to reach $3.02 billion, boasting a compound annual growth rate (CAGR) of 4.4%. The growth during the forecast period is likely due to factors such as improved access to global healthcare, genetic risk evaluation, telemedicine, remote surveillance, as well as patient education and support. Looking toward the future, one can expect trends like extended thromboprophylaxis, innovative oral anticoagulants, customized treatment approaches, and sophisticated diagnostic imaging techniques.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13001

How Are Emerging Segments Shaping the Venous Thromboembolism Market Landscape?
The venous thromboembolism market covered in this report is segmented -

1) By Type: Deep Vein Thrombosis, Pulmonary Embolism, Other Types
2) By Treatment: Anti-Clotting Medications, Mechanical Devices, Thrombolytic Therapy, Other Treatment
3) By End Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:
1) By Deep Vein Thrombosis (DVT): Proximal DVT, Distal DVT, Asymptomatic DVT
2) By Pulmonary Embolism (PE): Acute PE, Chronic PE, Submassive PE
3) By Other Types: Thrombophlebitis, Superficial Vein Thrombosis, Post-Thrombotic Syndrome

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13001&type=smp

Which Growth Factors Are Influencing Venous Thromboembolism Market Expansion?
The strengthening and growth of the healthcare infrastructure are predicted to fuel the venous thromboembolism market growth in the future. The healthcare industry encompasses the consolidation of various sectors of an economic system, all working towards products and services that aim to heal, prevent, rehabilitate and offer palliative care for patients. The growth of this industry aids in developing crucial infrastructures, practices, policies, and educational programs needed for the implementation of VTE prevention protocols. As an illustration, in May 2023, the American Health Care Association, a nonprofit organization in the US, revealed a growth in the number of US hospitals from 6,093 in 2022 to 6,129. Another significant highlight in May 2023 was from the Office for National Statistics, a statistics authority in the UK which reported a healthcare expenditure of approximately £292 billion in 2023, indicating a 5.6% nominal increase. Further, there was a 2.8% real-term rise in the long-term health and social care expenditure in 2022. Thus, the growth of the healthcare industry is significantly contributing to the expansion of the venous thromboembolism market. The anticipated rise in orthopedic procedures will further enhance the venous thromboembolism market in the future. Orthopedic procedures are surgeries aimed at rectifying conditions of the spine and joints as well as skeletal deformations. Several of such procedures, including total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery (HFS), have a high VTE risk. This has resulted in the increased use of compression devices for DVT prophylaxis, aimed at preventing the formation of blood clots in the deep veins of legs that can induce venous thromboembolism (VTE). Substantiating this, a study published by the National Library of Medicine, a US-based biomedical library, in February 2023, predicts a substantial increase in THA and TKA procedures to 719,364 and 1,222,988 respectively by 2040. Furthermore, it is anticipated that by 2060, TKAs will reach 2,917,959, while THAs will total 1,982,099. Therefore, the projected growth in orthopedic procedures is set to drive the venous thromboembolism market further.

Who Are the Dominant Players Across Different Venous Thromboembolism Market Segments?
Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

What Are the Latest Developing Trends in the Venous Thromboembolism Market?
Leading firms in the venous thromboembolism market are innovating and introducing novel anticoagulant medications in an effort to maintain market dominance. These advancements in anticoagulants can potentially produce more effective treatments for preventing or curing venous thromboembolism. For example, Anthos Therapeutics, an American company specializing in clinical-stage biotherapeutics, gained official approval in September 2022 from the US Food and Drug Administration (FDA) for their new anticoagulant medicine, abelacimab. This new, fully human monoclonal antibody drug is designed to prevent stroke and systemic embolism in patients with atrial fibrillation. The innovative, once-monthly, dual-action antibody, abelacimab, is engineered to promote hemostasis-sparing anticoagulation by blocking Factor XI.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

Which Geographic Regions Are Expected to Dominate the Venous Thromboembolism Market in the Coming Years?
North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Venous Thromboembolism Market?
2. What is the CAGR expected in the Venous Thromboembolism Market?
3. What Are the Key Innovations Transforming the Venous Thromboembolism Industry?
4. Which Region Is Leading the Venous Thromboembolism Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Venous Thromboembolism Market Anticipated To Witness Robust Growth, Surpassing $3.02 Billion By 2029 here

News-ID: 4033550 • Views:

More Releases from The Business Research Company

Segment Evaluation and Major Growth Areas in the Personalized Testing and Supplements Market
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future. Market Valuation and Expansion Forecast for Personalized Testing
Top Players and Market Competition in the Skin Microbiome Industry
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry. Projected Expansion in the Skin
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market Landscape
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory. Steady Growth Expected in Upadacitinib Market Size Through 2029 The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Market
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field. Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics

All 5 Releases


More Releases for Venous

Key Trends Reshaping the Chronic Venous Occlusions Treatment Market: Introductio …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Chronic Venous Occlusions Treatment Market Size Growth Forecast: What to Expect by 2025? The market dedicated to therapies for chronic venous occlusions has experienced robust expansion lately, projected to increase from a valuation of $6.7 billion in 2024 to $7.15 billion the following year, reflecting a consistent compound annual
States Venous Stents Market Projected to Witness Expansion with Rising Incidence …
States Venous Stents Market Overview The States Venous Stents Market is expected to grow from USD 1.3 billion in 2025 to USD 2.4 billion by 2032, registering a CAGR of 8.9%. Coherent Market Insights is pleased to release its latest States Venous Stents Market research report, offering an in-depth analysis of the U.S. States Venous Stents Market Landscape from 2025 to 2032. This report delivers reliable projections across national and regional levels,
Venous Stent Market Grows with Rising Cases of Chronic Venous Disorders | Boston …
Venous Stent Market Overview The venous stent market is anticipated to grow from USD 0.6 billion in 2025 to USD 1.3 billion by 2032, exhibiting a CAGR of 10.3% during the forecast period. Coherent Market Insights is proud to announce the release of its latest market research report, providing a comprehensive analysis of the Venous Stent Market Landscape from 2025 to 2032. This report delivers precise forecasts across global, regional, and country
Major Force in the Venous Thromboembolism Market 2025: Impact Of Healthcare Infr …
How Will the Venous Thromboembolism Market Grow, and What Is the Projected Market Size? Over the past few years, the venous thromboembolism market has experienced a steady increase in its size. It's projected to expand from $2.44 billion in 2024 to $2.55 billion in 2025, rising at a compound annual growth rate (CAGR) of 4.4%. The growth during the historic period can be credited to an increasing elderly population, progress in
Venous Catheter Market Size 2024 to 2031.
Market Overview and Report Coverage A venous catheter is a small, flexible tube inserted into a vein for medical purposes such as accessing the bloodstream for medications, fluids, or blood sampling. The venous catheter market is expected to witness significant growth in the coming years, with a projected CAGR of 6.30% during the forecasted period. The current outlook for the venous catheter market is positive, driven by factors such as
Increasing Prevalence of Venous Thromboembolism to Augment Growth of the Venous …
Venous thromboembolism (VTE) is the formation of blood clots in the bloodstream. Two main types of venous thromboembolism are pulmonary embolism and deep vein thrombosis. The formation of blood clots in a deep vein is called deep vein thrombosis, while the deep vein thrombosis formed breaks the clot and travels to the lungs, known as pulmonary embolism. Sample Copy Of Report @ https://www.coherentmarketinsights.com/insight/request-sample/188 Pulmonary embolism occurs in almost one-third of patients